CROMOLYN SODIUM OPHTHALMIC SOLUTION USP, 4% Sterile

Manufacturer
A-S Medication Solutions
Effective date
2023-02-06
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
10
Source
legacy-cache
Hydrated at
2026-08-01 21:37:50

Label at a glance#

ProductCromolyn Sodium
Active ingredientCROMOLYN SODIUM
Label structure11 sections

Indications and uses

Cromolyn Sodium Ophthalmic Solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

Dosage and administration

The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium. Patients should be advised that the effect of Cromolyn Sodium Ophthalmic Solution therapy is dependent upon its administration at regular intervals, as directed. Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Cromolyn Sodium Ophthalmic Solution USP, 4% is a clear, colorless, sterile solution intended for topical ophthalmic use.

Cromolyn Sodium is represented by the following structural formula:

Structural Formula
Structural Formula

Chemical Name: disodium 5-5' - [(2-hydroxytrimethylene)dioxy] bis [4-oxo-4H-1-benzopyran-2-carboxylate].

Pharmacologic Category: Mast cell stabilizer.

Each mL contains: Active: Cromolyn sodium 40 mg (4%); Inactives: Edetate disodium 0.1% and Water for Injection. It has a pH of 4.0 to 7.0; Preservative: Benzalkonium chloride 0.01%.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell.

Another activity demonstrated in vitro is the capacity of cromolyn sodium to inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators. Another study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate.

Cromolyn sodium has no intrinsic vasoconstrictor, antihistamine, or anti-inflammatory activity.

Cromolyn sodium is poorly absorbed. When multiple doses of cromolyn sodium ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of cromolyn sodium is absorbed into the systemic circulation (presumably by way of the eye, nasal passages: buccal cavity and gastrointestinal tract). Trace amounts (less than 0.01%) of the cromolyn sodium dose penetrate into the aqueous humor and clearance from this chamber is virtually complete within 24 hours after treatment is stopped.

In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of cromolyn sodium is absorbed following administration to the eye.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Cromolyn Sodium Ophthalmic Solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Cromolyn Sodium Ophthalmic Solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients.

PRECAUTIONS

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: Patients may experience a transient stinging or burning sensation following application of Cromolyn Sodium Ophthalmic Solution.

The recommended frequency of administration should not be exceeded (see DOSAGE AND ADMINISTRATION).

INFORMATION FOR PATIENTS SECTION

Information for Patients: Patients should be advised to follow the patient instructions listed on the Information for Patient's sheet.

Users of contact lenses should refrain from wearing lenses while exhibiting the signs and symptoms of vernal keratoconjunctivitis, vernal conjunctivitis, or vernal keratitis. Do not wear contact lenses during treatment with Cromolyn Sodium Ophthalmic Solution.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long term studies of Cromolyn Sodium in mice (12 months intraperitoneal administration at doses up to 150 mg/kg three days per week): hamsters (intraperitoneal administration at doses up to 52.6 mg/kg three days per week for 15 weeks followed by 17.5 mg/kg three days per week for 37 weeks), and rats (18 months subcutaneous administration at doses up to 75 mg/kg six days per week) showed no neoplastic effects. The average daily maximum dose levels administered in these studies were 192.9 mg/m2 for mice, 47.2 mg/m2 for hamsters and 385.8 mg/m2 for rats. These doses correspond to approximately 6.8,1.7, and 14 times the maximum daily human dose of 28 mg/m2.

Cromolyn Sodium showed no mutagenic potential in the Ames Salmonella/microsome plate assays, mitotic gene conversion in Saccharomyces cerevisiae and in an In vitro cytogenetic study in human peripheral lymphocytes.

No evidence of impaired fertility was shown in laboratory reproduction studies conducted subcutaneously in rats at the highest doses tested, 175 mg/kg/day (1050 mg/m2) in males and 100 mg/kg/day (600 mg/m2) in females. These doses are approximately 37 and 21 times the maximum daily human dose, respectively, based on mg/m2.

Pregnancy

PREGNANCY SECTION

TERATOGENIC EFFECTS SECTION

Teratogenic Effects: Pregnancy Category B. Reproduction studies with cromolyn sodium administered subcutaneously to pregnant mice and rats at maximum daily doses of 540 mg/kg (1620 mg/m2) and 164 mg/kg (984 mg/m2), respectively, and intravenously to rabbits at a maximum daily dose of 485 mg/kg (5820 mg/m2) produced no evidence of fetal malformation. These doses represent approximately 57, 35, and 205 times the maximum daily human dose, respectively, on a mg/m2 basis. Adverse fetal effects (increased resorption and decreased fetal weight) were noted only at the very high parenteral doses that produced maternal toxicity. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

NURSING MOTHERS SECTION

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cromolyn Sodium Ophthalmic Solution is administered to a nursing woman.

PEDIATRIC USE SECTION

Pediatric Use: Safety and effectiveness in children below the age of 4 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequently reported adverse reaction attributed to the use of cromolyn sodium, on the basis of reoccurrence following readministration, is transient ocular stinging or burning upon instillation.

The following adverse reactions have been reported as infrequent events. It is unclear whether they are attributed to the drug:

Conjunctival injection; watery eyes; itchy eyes; dryness around the eye; puffy eyes; eye irritation; and styes.

Immediate hypersensitivity reactions have been reported rarely and include dyspnea, edema, and rash.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium.

Patients should be advised that the effect of Cromolyn Sodium Ophthalmic Solution therapy is dependent upon its administration at regular intervals, as directed.

Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement.

If required, corticosteroids may be used concomitantly with Sodium Chloride Ophthalmic Solution.

HOW SUPPLIED

HOW SUPPLIED SECTION

Product: 50090-3042

NDC: 50090-3042-0 10 mL in a BOTTLE, DROPPER / 1 in a CARTON

SPL PATIENT PACKAGE INSERT SECTION

Information for the Patient

Cromolyn Sodium Ophthalmic Solution USP, 4% Sterile

It is important to use Cromolyn Sodium Ophthalmic Solution regularly, as directed by your physician.

  1. Thoroughly wash your hands.
  2. Remove safety seal (Figure 1).Figure 1Figure 1
  3. Remove cap (Figure 2).Figure 2Figure 2
  4. Sit or stand comfortably, with your head tilted back (Figure 3).Figure 3Figure 3
  5. Open eyes, look up, and draw the lower lid of your eye down gently with your index finger (Figure 4).Figure 4Figure 4
  6. Hold the Cromolyn Sodium Ophthalmic Solution bottle upside down. Place dropper tip as close as possible to the lower eyelid and gently squeeze out the prescribed number of drops (Figure 5).Figure 5Figure 5
  7. Do not touch the eye or eyelid with the dropper tip.
  8. Blink a few times to make sure the eye is covered with the solution.
  9. Close your eye and remove any excess solution with a clean tissue.
  10. Repeat process in the other eye.

Special Tips:

  1. Avoid placing Cromolyn Sodium Ophthalmic Solution directly on the cornea (the area just over the pupil), because it is especially sensitive. You will find the administration of eye drops more comfortable if you place the drops just inside the lower eyelid as shown in Figure 5 on the previous page.
  2. To avoid contamination of the solution, do not touch dropper tip to the eye, fingers, or any other surface. Replace cap after use. It is recommended that any remaining contents be discarded after the treatment period prescribed by your physician.
  3. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light — store in original carton.
  4. Keep tightly closed and out of the reach of children.
  5. Do not use with any other ocular medication unless directed by your physician. Do not wear contact lenses during treatment with Cromolyn Sodium Ophthalmic Solution.

Akorn
Manufactured By:
AKORN, INC.
Lake Forest, IL 60045
Rev. 06/16

Cromolyn Sodium

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label Image
Label Image

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-3042-0ML - Milliliter50090-30421ab09f86-a6f8-4b0c-8707-5e9f7d09723112018-11-06
17478-291-11ML - Milliliter17478-2914402d7f0-5460-4224-a508-e4d16d39f46612012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50090-304250090-3042-0
17478-291

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074706-001CROMOLYN SODIUMCROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2984e616aacf4f…
2026-08-18 06:07:402026-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-293f01610625f2…
2019-09-15 20:21 UTC2019-09A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074706-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074706-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074706-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074706-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074706-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074706-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074706-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A074706-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074706-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074706-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074706-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A074706-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A074706-001AT1ea99ee380514…
2023-01-26 05:58 UTC2023-01A074706-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074706-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074706-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A074706-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A074706-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
5aac8a19-1c38-49ac-9bce-a953d09ab9acdca35b62-18dc-436d-8996-ed31a5dfddfb2024-03-21Adverse reactionsExact identifier
spl set id: dca35b62-18dc-436d-8996-ed31a5dfddfb

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.